Epithalon (Epitalon) vs ARA-290: What the Research Actually Compares
A comparison of the published research on Epithalon (Epitalon) and ARA-290, covering what each compound is, what studies measured, where evidence is stronger, and what remains unknown.
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, classified as a synthetic peptide. ARA-290 (also known as cibinetide) is a synthetic 11-amino acid peptide derived from the structure of erythropoietin, classified as an innate repair receptor agonist. The identifiers for Epithalon include its tetrapeptide sequence and its role as a telomerase-related research peptide; ARA-290 is identified by its linear sequence and its classification as a non-hematopoietic erythropoietin analogue. The research on Epithalon (Epitalon) centres on telomerase activation and telomere elongation pathways, while the work on ARA-290 centres on the innate repair receptor (IRR), a heteromeric receptor complex that includes the erythropoietin receptor and the beta-common receptor.
Both compounds have been examined in preclinical and clinical settings, but the published evidence differs in scope, model systems, and outcome measures. The sections below summarise what the literature reports for each, without declaring a winner.
Research Studies
Epithalon and telomerase activity in human somatic cells
Epithalon has been studied for its effects on telomerase activity in human somatic cells. In vitro work has examined whether the tetrapeptide can induce telomerase expression and elongate telomeres in cultured fibroblasts and other cell types. These studies typically measure telomerase reverse transcriptase (TERT) expression and telomere length over multiple cell divisions. The findings are largely limited to cell culture systems, and the evidence does not extend to whole-organism outcomes in humans.
Epithalon and telomere length in animal models
Animal studies have investigated Epithalon administration in rodents and other species, with endpoints including telomere length in various tissues, lifespan, and age-related biomarkers. Some reports describe telomere elongation in somatic tissues after repeated administration, but these studies are often small and have not been replicated in large independent cohorts. The evidence for Epithalon in animal models is preliminary and does not establish causal relationships in humans.
Epithalon and neuroendocrine regulation in aging models
Research has explored Epithalon's effects on neuroendocrine function, particularly melatonin secretion and circadian rhythms, in aged animals. These studies measure pineal gland function and hormone levels, with some reporting restoration of youthful patterns. The mechanisms proposed involve epigenetic regulation of gene expression, but the evidence is confined to animal models and does not include human clinical trials.
ARA-290 and diabetic macular oedema in type 1 or 2 diabetes
A phase II clinical trial (NCT06626971) examined ARA-290 in patients with type 1 or 2 diabetes and diabetic macular oedema (DMO) [1]. The study was a prospective, open-label, interventional, single-centre, investigator-led trial. Participants received ARA-290 at a daily dose of 4 mg subcutaneously for 12 weeks. The primary objective was to determine whether ARA-290 had a beneficial effect on mean change in best corrected visual acuity (BCVA) from baseline to week 12 [1]. This trial provides human data on a specific ocular outcome in a defined diabetic population.
ARA-290 and corneal nerve fiber density in sarcoidosis
A clinical study (NCT02039687) evaluated ARA-290 for neuropathic symptoms in subjects with sarcoidosis and small fiber neuropathy [2]. The study administered ARA-290 or placebo by subcutaneous injection daily for 28 days. The rationale described in the study record is that brief interaction of ARA-290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in various cells, tissues, and organs, activating repair mechanisms and accelerating healing, including nerve damage associated with sarcoidosis [2]. The study monitored safety and symptoms of small fiber neuropathy. This trial provides human data on corneal nerve fiber density and neuropathic symptoms in a sarcoidosis population.
ARA-290 and glucose metabolism in prediabetes and type 2 diabetes
A clinical trial (NCT01933529) investigated ARA-290 in persons with prediabetes (impaired glucose tolerance or impaired fasting glucose) or drug-naive type 2 diabetes [3]. The purpose was to determine whether ARA-290, a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion. The study also evaluated effects on insulin sensitivity and serum levels of inflammatory agents such as cytokines. Safety was monitored by following parameters related to hematology, kidney and liver function, and lipid levels [3]. This trial provides human data on metabolic and inflammatory endpoints in a prediabetic and type 2 diabetic population.
ARA-290 and cognitive and neural processing of emotions in healthy volunteers
A study (NCT02070783) examined the cognitive and neural effects of ARA-290 in healthy volunteers [4]. The background notes that erythropoietin (EPO) may have antidepressant properties but can cause serious side-effects with repeated administration, such as thrombosis. ARA-290 is a peptide that does not have the effects of EPO on blood cells but may still affect brain function. The study aimed to replicate previous findings with a single dose of EPO in healthy volunteers by studying the effects of ARA-290 on the cognitive and neural processing of emotions. The hypothesis was that a single dose of ARA-290 would lead to a positive shift in information processing compared to placebo, 7 days post-administration [4]. This trial provides human data on cognitive and neural outcomes in a healthy volunteer population.
Epithalon and ARA-290: comparison of evidence scope
The table below summarises the key differences in the published research for each compound.
| Feature | Epithalon (Epitalon) | ARA-290 |
|---|---|---|
| Class | Synthetic tetrapeptide | Synthetic 11-amino acid peptide; innate repair receptor agonist |
| Primary pathway | Telomerase activation, telomere elongation | Innate repair receptor (IRR) |
| Human clinical trial data | Not identified in the evidence block | Multiple trials: DMO [1], sarcoidosis [2], prediabetes/T2D [3], healthy volunteers [4] |
| Animal model data | Reported in aging and neuroendocrine studies | Not specified in the evidence block |
| In vitro data | Reported in telomerase studies | Not specified in the evidence block |
| Outcome measures | Telomere length, telomerase activity, hormone levels | BCVA, corneal nerve fiber density, glucose, insulin sensitivity, cytokines, cognitive processing |
Where the evidence is stronger for each compound
For ARA-290, the evidence includes multiple registered human clinical trials with defined populations and endpoints, such as diabetic macular oedema [1], sarcoidosis with small fiber neuropathy [2], prediabetes and type 2 diabetes [3], and healthy volunteers [4]. These trials provide data on safety and specific outcome measures in humans. For Epithalon, the evidence identified in this block is limited to preclinical studies, including in vitro telomerase assays and animal models of aging and neuroendocrine function. No human clinical trial data for Epithalon are present in the evidence block. Therefore, the literature supports a stronger clinical evidence base for ARA-290 in the specific conditions studied, while Epithalon's evidence is confined to laboratory and animal research.
What is simply not known
For Epithalon, it is not known whether the telomerase activation and telomere elongation observed in vitro and in animal models translate to humans. The long-term safety and efficacy of Epithalon in human populations have not been established in the evidence block. For ARA-290, while human trials exist, the evidence block does not provide results or outcomes from those trials; it only describes their objectives and designs. It is not known whether ARA-290 achieved its primary endpoints in any of the listed studies. Additionally, the comparative effects of Epithalon versus ARA-290 have not been directly studied in any trial identified here. No head-to-head studies are present in the evidence block.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema
- [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
- [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
- [4] Cognitive and Neural Effects of ARA290
- [5] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.